Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Madroszyk · SciRah

Researcher profile · Semantic Scholar

A. Madroszyk

Share profile

A. Madroszyk — researcher profile on SciRah

h-index: 21
Works: 98
Citations: 2,235

Most-cited papers

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
E. Quoix, R. Ramlau, V. Westeel, Z. Pápai +17 more
2011The Lancet Oncology279 citations
Semantic Scholar
Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
B. Besse, S. Le Moulec, J. Mazières, H. Sénellart +18 more
2015Clinical Cancer Research218 citations Open access
Semantic Scholar
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
E. Quoix, H. Léna, G. Losonczy, F. Forget +18 more
2016The Lancet Oncology196 citations
Semantic Scholar
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).
C. Chouaid, C. Dujon, P. Dô, I. Monnet +14 more
2014Lung Cancer179 citations
Semantic Scholar
Role of molds in farmer's lung disease in Eastern France.
G. Reboux, R. Piarroux, F. Mauny, A. Madroszyk +3 more
2001American Journal of Respiratory and Critical Care Medicine142 citations
Semantic Scholar
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
N. Baize, I. Monnet, L. Greillier, M. Geier +18 more
2020The Lancet Oncology133 citations Open access
Semantic Scholar
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
E. Guardiola, F. Peyrade, L. Chaigneau, Didier Cupissol +8 more
2004European Journal of Cancer122 citations
Semantic Scholar
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.
B. Besse, E. Felip, R. Campelo, M. Cobo +64 more
2023Annals of Oncology76 citations Open access
Semantic Scholar
Reassessment of scoring systems and prognostic factors for metastatic spinal cord compression.
E. Tabouret, C. Cauvin, S. Fuentès, B. Esterni +6 more
2015The spine journal71 citations
Semantic Scholar
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
J. Remon, B. Besse, S. Aix, A. Callejo +18 more
2023Annals of Oncology70 citations Open access
Semantic Scholar
Bronchoalveolar lavage in hypersensitivity pneumonitis: a series of 139 patients.
D. Caillaud, J. Vergnon, A. Madroszyk, B. Melloni +2 more
2012Inflammation & Allergy - Drug Targets60 citations
Semantic Scholar
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
F. Bertucci, A. Gonçalves, A. Guille, J. Adélaı̈de +30 more
2021Genome Medicine48 citations Open access
Semantic Scholar
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
I. Borget, J. Cadranel, J. Pignon, E. Quoix +9 more
2011European Respiratory Journal44 citations Open access
Semantic Scholar
Small-cell carcinoma of the esophagus: report of three cases and review of the literature with emphasis on therapy.
A. Madroszyk, J. Egreteau, L. Martín, P. Queneau +2 more
2001Annals of Oncology37 citations Open access
Semantic Scholar
LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
N. Girard, J. Mazières, J. Otto, H. Léna +16 more
2021Annals of Oncology33 citations Open access
Semantic Scholar
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
J. Remon, B. Besse, A. Leary, I. Bièche +13 more
2020JTO Clinical and Research Reports28 citations Open access
Semantic Scholar
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
J. Remon, B. Besse, S. Aix, Ana Callejo +18 more
2024Journal of Clinical Oncology27 citations Open access
Semantic Scholar
Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer.
R. Sabatier, E. Nicolas, Maria Paciencia, A. Jonville-béra +8 more
2018Journal of Geriatric Oncology24 citations
Semantic Scholar
Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
F. Bertucci, A. Gonçalves, G. Monges, A. Madroszyk +5 more
2006Oncology Report24 citations Open access
Semantic Scholar
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
L. Falchero, F. Guisier, M. Darrason, Arnaud Boyer +20 more
2023Lung Cancer23 citations Open access
Semantic Scholar
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
C. Chouaid, T. Filleron, D. Debieuvre, M. Pérol +18 more
2021Targeted oncology21 citations
Semantic Scholar
Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
M. Gilabert, F. Bertucci, B. Esterni, A. Madroszyk +5 more
2010Anticancer Research20 citations
Semantic Scholar
Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France
L. Bigay-Gamé, S. Bota, L. Greillier, I. Monnet +8 more
2018Oncology19 citations
Semantic Scholar
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
M. Sassier, A. Dugué, B. Clarisse, P. Lesueur +17 more
2015Lung Cancer19 citations
Semantic Scholar
1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
G. Giaccone, E. Felip, M. Cobo, R. Campelo +16 more
2020Annals of Oncology18 citations Open access
Semantic Scholar
First-Line Afatinib plus Cetuximab for EGFR-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study
A. Cortot, A. Madroszyk, E. Giroux-Leprieur, O. Molinier +18 more
2021Clinical Cancer Research17 citations
Semantic Scholar
Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
S. Loubière, A. Drezet, M. Beau-Faller, D. Moro-Sibilot +17 more
2018European Respiratory Journal17 citations Open access
Semantic Scholar
Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer.
Angélique Melia, E. Fockens, P. Sfumato, C. Zemmour +3 more
2022Joint Bone Spine16 citations Open access
Semantic Scholar
Non-small cell lung cancer, locally advanced
S. Ou, D. Camidge, J. Engelman, Jeffrey W. Clark +222 more
201216 citations Open access
Semantic Scholar
Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
R. Ramlau, V. Westeel, Z. Pápai, A. Rivière +6 more
200816 citations
Semantic Scholar
Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup.
J. Soria, F. Barlesi, B. Besse, J. Mazières +16 more
201315 citations
Semantic Scholar
[Respective influence of occupational and personal factors on respiratory function in dairy farmers].
D. Choma, Virginie Westeel, A. Dubiez, D. Góra +8 more
1998Revue des maladies respiratoires15 citations
Semantic Scholar
BetaHCG secretion by a pulmonary adenocarcinoma
C. Vicier, E. Tabouret, A. Tallet, A. Gonçalves +3 more
2013World Journal of Surgical Oncology14 citations Open access
Semantic Scholar
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.
M. Wislez, C. Mascaux, J. Cadranel, Q. Thomas +15 more
2025European Journal of Cancer12 citations Open access
Semantic Scholar
Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review
P. Rochigneux, Alejandro J. Garcia, B. Chanez, A. Madroszyk +2 more
2020Frontiers in Immunology12 citations Open access
Semantic Scholar
[Diffuse interstitial pneumonia revealing Erdheim-Chester's disease].
A. Madroszyk, B. Wallaert, M. Rémy, J. Remy +3 more
1994Revue des maladies respiratoires12 citations
Semantic Scholar
Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report
J. Leblanc, S. Hoibian, A. Boucraut, J. Ratone +7 more
2021Frontiers in Immunology11 citations Open access
Semantic Scholar
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis
K. Amrane, B. Cabarrou, G. Justeau, S. Schneider +16 more
2025ESMO Open10 citations
Semantic Scholar
Clinical characteristics and management of long survivors in extensive stage small cell lung cancer.
E. Gobbini, M. H. Diallo, D. Pasquier, S. Schneider +16 more
2025Lung Cancer9 citations Open access
Semantic Scholar
Perineal Small Bowel Fistula After Pelvic Exenteration for Cancer: Technical Guidelines for Perineal Fistula
O. Turrini, J. Guiramand, V. Moutardier, F. Viret +7 more
2006Annals of Surgical Oncology9 citations
Semantic Scholar
Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.
F. Barlesi, P. Tomasini, M. Karimi, S. Michiels +30 more
2022Clinical Cancer Research8 citations Open access
Semantic Scholar
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records
M. Beaufils, V. Amodru, M. Tejeda, J. Boher +15 more
2023Journal for ImmunoTherapy of Cancer7 citations Open access
Semantic Scholar
Mass cytometry reveals classical monocytes, NK cells and ICOS+ CD4+ T cells associated with pembrolizumab efficacy in lung cancer patients
P. Rochigneux, A. Lisberg, Alejandro J. Garcia, S. Granjeaud +14 more
2022Clinical Cancer Research7 citations Open access
Semantic Scholar
OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial
N. Baize, I. Monnet, L. Greillier, M. Geier +16 more
2019Journal of Thoracic Oncology7 citations Open access
Semantic Scholar
Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control.
M. Tyran, N. Charrier, J. Darréon, A. Madroszyk +2 more
2018In Vivo7 citations Open access
Semantic Scholar
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
G. Zalcman, A. Madroszyk, C. Dayen, O. Molinier +16 more
2023Journal of Clinical Oncology6 citations
Semantic Scholar
ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.
E. Felip, G. Giaccone, R. Dziadziuszko, F. Denis +16 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
J. Mazières, F. Barlesi, I. Rouquette, B. Besse +17 more
20185 citations
Semantic Scholar
Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung).
A. Cortot, A. Madroszyk, Etienne Giroux Leprieur, O. Molinier +14 more
2019Journal of Clinical Oncology4 citations
Semantic Scholar
A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study
B. Chanez, F. Bertucci, M. Gilabert, A. Madroszyk +4 more
2017Supportive Care in Cancer4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Debieuvre×12
Invite
D. Debieuvre — researcher profile on SciRah
B. Besse×10
Invite
B. Besse — researcher profile on SciRah
E. Quoix×9
Invite
E. Quoix — researcher profile on SciRah
V. Westeel×9
Invite
V. Westeel — researcher profile on SciRah

×9

Invite

H. Léna — researcher profile on SciRah

Invite

R. Gervais — researcher profile on SciRah

Invite

F. Morin — researcher profile on SciRah

J. Mazières×8

Invite

J. Mazières — researcher profile on SciRah

Invite

C. Chouaid — researcher profile on SciRah

Invite

L. Falchero — researcher profile on SciRah

Invite

G. Robinet — researcher profile on SciRah

D. Moro-Sibilot×7

Invite

D. Moro-Sibilot — researcher profile on SciRah